Pipelines

XM182-Exatecan is a first-in-class IL13Rα2-targeted polypeptide-drug conjugate designed to deliver sustained, tumor-selective drug exposure, with over 97% tumor retention and exposure lasting more than 30 days. In preclinical studies, XM182-Exatecan demonstrated near-complete tumor regression with no recurrence, highlighting its potential as a novel therapeutic approach for CNS tumors and its future applicability to hard-to-penetrate solid tumors. The candidate has received FDA Orphan Drug Designation, marking an important milestone in its development. A first-in-human clinical trial is anticipated in Q3 2028.

Excellamol is advancing five OncoPDC programs targeting hard-to-treat, high-mortality cancers, including glioblastoma (GBM), pediatric diffuse midline glioma, and pancreatic ductal adenocarcinoma. Through three FDA INTERACT and one Type D meeting, Excellamol has achieved key regulatory alignment, significantly de-risking the development pathway toward IND submission and a planned first-in-human trial of its lead GBM candidate XM182-Exatecan in 2028.